Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST




Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer

Ning Ren, Zhenmin Tian, Hongmei Sun, Xiaofei Lu

Department of Otorhinolaryngology, YIDU Central Hospital, Weifang, Shandong, China (mainland)

Med Sci Monit 2020; 26:e924590

DOI: 10.12659/MSM.924590

Available online: 2020-06-20

Published: 2020-08-22

BACKGROUND: Papillary thyroid cancer (PTC) is the most common histological type of thyroid cancer. Most PTC patients have favorable outcomes, but 10% of patients still have distant metastases at presentation or during follow-up. Dynamin 2 (DNM2) is the only DNM ubiquitously expressed in human tissues, but its expression and clinical significance in PTC is still unknown.
MATERIAL AND METHODS: In our study, we investigated the expression of DNM2 in 112 cases of PTC and classified the patients into low and high expression of DNM2. The clinical significance of DNM2 was evaluated by assessing its correlation with the clinicopathological parameters with the chi-square method. The correlations between DNM2 expression and the disease-free survival rate or overall survival rate were assessed with the Kaplan-Meier method and the log-rank test. The independent prognostic factors of PTC were determined by the Cox-regression hazard model.
RESULTS: Patients with low and high DNM2 expression accounted for 75% and 25% respectively in the 112 patients with PTC. High DNM2 expression was significantly associated with recurrence (P=0.014) and poor prognosis (P=0.004). In addition to tumor stage, DNM2 expression was an independent prognostic biomarker of PTC, indicating an unfavorable prognosis.
CONCLUSIONS: DNM2 was an independent PTC biomarker indicating more likely recurrence and poorer prognosis. Detecting DNM2 expression may help to select the high-risk patients for adjuvant therapy.

Keywords: Biological Markers, Dynamin II, Prognosis, Recurrence, Thyroid Neoplasms